Clinical survival predictors in patients with advanced cancer

Archives of Internal Medicine

Volumn 160, Issue 6, 2002, Pages 861-868

  Viganó, Antonio ^a,d   Bruera, Eduardo ^a,b   Jhangri, Gian S ^a   Newman, Stephen C ^a   Fields, Anthony L ^a   Suarez Almazor, Maria E ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; LABORATORY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0342749460     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.6.861     Document Type: Article

References (111)

1. Fraumeni JF, Devesa SS, Hoover R, Kinlen L. Epidemiology of cancer. In: De Vita V, Hellman S, Rosemberg S, eds. Cancer Principles and Practice of Oncology, 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1994:150-182.
2. WHO Expert Committee. Cancer Pain Relief and Palliative Care. Geneva, Switzerland: World Health Organization; 1990.
3. Parkes CM. Home or hospital? terminal care as seen by surviving spouses. J R Coll Gen Pract. 1978;28:19-30.
4. Calman KC. Physical aspects. In: Saunders C, ed. The Management of Terminal Disease. New York, NY: Edward Arnold Publisher/Chapman & Hall; 1978:33-43.
5. Saunders CM. Appropriate treatment, appropriate death. In: Saunders C. ed. The Management of Terminal Disease. New York, NY: Edward Arnold Publisher/Chapman & Hall; 1978:1-18.
6. McCusker J. The terminal period of cancer: definition and descriptive epidemiology. J Chronic Dis. 1984;37:377-385.
7. Twycross RG, Lichter I. The terminal phase. In: Doyle D, Hanks G, MacDonald N, eds. Oxford Textbook of Palliative Medicine. New York, NY: Oxford University Press; 1993:649-661.
8. Hoy AM. Clinical pointers to prognosis in terminal disease. Dev Oncol. 1987; 48:79-88.
9. Enck RE. Prognostication of survival in hospice care. Am J Hosp Palliat Care. 1990;2:9-11.
10. Miller R. Predicting survival in the advanced cancer patients. Henry Ford Hosp Med J. 1991;39:81-84.
11. Lassauniere JM, Vinant P. Prognostic factors, survival and advanced cancer. J Palliat Care. 1992;8:52-54.
12. Maltoni M, Pirovano M, Nanni O, Labianca R, Amadori D. Prognostic factors in terminal cancer patients. Eur J Palliat Care. 1994;1(3):122-125.
13. Den Daas N. Estimating length of survival in end-stage cancer: a review of the literature. J Pain Symptom Manage. 1995;10:548-555.
14. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Cancer. 1995;75:2613-2622.
15. Wright K, Dyck S. Expressed concerns of adult cancer patients' family members. Cancer Nurs. 1984;10:371-374.
16. Lewandowsky W, Jones S. The family with cancer: nursing interventions throughout the course of living with cancer. Cancer Nurs. 1988;11:313-321.
17. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148:1586-1591.
18. Forster LE, Lynn J. The use of physiologic measures and demographic variables to predict longevity among inpatient hospice applicants. Am J Hosp Care. 1989; 6(2):31-34.
19. Kinzbrunner BM. Ethical dilemmas in hospice and palliative care. Support Care Cancer. 1995;3:28-36
20. Regional Palliative Care Program, 1997 Annual Report for the Regional Palliative Care Program. Edmonton, Alberta: Regional Palliative Care Program; 1997.
21. National Hospice Organization (NHO) Newsline. 1992 stats show continued growth in programs and patients. NHO Newsline. 1993;3:1-2.
22. Demer C, Johnston-Anderson AV, Tobin R, et al. Cost of hospice care: late vs early entry [abstract]. In: Programs and Proceedings of the American Society of Clinical Oncology, Twenty-eighth Annual Meeting, San Diego, Calif, May 17-19, 1992. Vol 11. Alexandria, Va: American Society of Clinical Oncology; 1992:392.
23. Brody H, Lynn J. The physician's responsibility under the new Medicare reimbursement for hospice care. N Engl J Med. 1984;310:920-922.
24. Parkes CM. Accuracy of predictions of survival in later stages of cancer. BMJ. 1972;2:29-31.
25. Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky Index help? Lancet. 1985;25:1204-1206.
26. Heyse-Moore LH, Johnson-Bell VE. Can doctors accurately predict the life expectancy of patients with terminal cancer? Palliat Med. 1987;1:165-166.
27. Forster LE, Lynn J. Predicting life span for applicants to inpatient hospice. Arch Intern Med. 1988;148:2540-2543.
28. Addington-Hall JM, MacDonald LD, Anderson HR. Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care? Br J Cancer. 1990;62:695-699.
29. Maltoni M, Nanni O, Derni S, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of the terminally ill cancer patients. Eur J Cancer. 1994;30A:764-766.
30. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220-2224.
31. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25-32.
32. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer, multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986;46:4189-4194.
33. Cassileth BR, Walsh W, Lusk EJ. Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol. 1988;6: 1753-1759.
34. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148:1586-1591.
35. Schonwetter RS, Teasdale TA, Storey P. The terminal cancer syndrome. Arch Intern Med. 1989;149:965-966.
36. Sorensen JB, Badsberg JH, Olsen J. The prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis in 259 patients. Cancer Res. 1989;49:5748-5754.
37. Schonwetter RS, Teasdale TA, Storey P, Luchi R. Estimation of survival in advanced cancer patients: an impedance to hospice admissions? Hospice J. 1990;6:65-79.
38. Bruera E, Miller MJ, Kuehn N, MacEachern T, Hanson J. Estimated survival of patients admitted to a palliative care unit: a prospective study. J Pain Symptom Manage. 1992;7:82-86.
39. Rosenthal MA, Gebski VJ, Kefford R, Stuart Harris RC. Prediction of lifeexpectancy in hospice patients: identification of novel prognostic factors Palliat Med. 1993:7:199-204.
40. Loprinzi CL, Laurie JA, Wieand HS, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol. 1994;12:601-607.
41. Schonwetter RS, Robinson BE, Ramirez G. Prognostic factors for survival in terminal lung cancer patients. J Intern Med. 1994;9:366-371.
42. Pesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol. 1995;13:1221-1230.
43. Allard P, Dionne A, Potvin D. Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care. 1995;11:20-24.
44. Buccheri G, Ferrigno D, Tamburini M, Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from asingle institution. Eur J Cancer. 1996;32A:1135-1141.
45. Wachtel T, Masterson SA, Reuben D, Goldberg R, Mor V. The end stage cancer patient: terminal common pathway. Hospice J 1988;4:43-80.
46. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: the importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol. 1989;15:235-242.
47. Ventafridda V, Ripamonti C, Tamburini M, Cassileth RB, De Conno F. Unendurable symptom as prognostic indicators of impending death in terminal cancer patients. Eur J Cancer. 1990;26:1000-1001.
48. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage. 1991;6:360-367.
49. Hardy RJ, Turner R, Sauders M, A'Hern R. Prediction of survival in a hospital based continuing care unit. Eur J Cancer. 1994;30A:284-288.
50. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995;10:423-431.
51. Cohen MH, Makuch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep. 1981;65:187-195.
52. Shoenfeld Y, Tal A, Berliner S, Pinknas J. Leukocytosis in non haematological malignancies: a possible tumor-associated marker. J Cancer Res Clin Oncol. 1986;111:54-58.
53. Ventafridda V, De Conno F, Saita L, Ripamonti C, Baronzio GF. Leucocytelymphocytes ratio as prognostic indicator of survival in cachectic cancer patients [letter]. Ann Oncol. 1991;2:196.
54. Maltoni M, Pirovano M, Nanni O, et al. Biological indices predictive of survival in 519 terminally ill cancer patients, J Pain Symptom Manage. 1997;13:1-9.
55. Fulop T, Herrmann F, Rapin CH. Prognostic role of serum albumin and prealbumin in elderly patients at admission to a geriatric hospital. Arch Gerontol Geriatr. 1991;12:31-39.
56. Herrmann FR, Safran C, Levkoff SF, Kenneth I. Serum albumin level on admission as a predictor of death, length of stay, and readmission Arch Intern Med. 1992;152:125-130.
57. Constans T, Bruyere A, Grab B, Rapin CH, PINI as a mortality index in hospitalized elderly patients [Research Note]. Int J Vitam Nutr Res. 1992;62:191.
58. Salamagne ME, Vinant-Binam P. Valeur pronostique de parametres biologiques de denutrition chez des patients hospitalises en unité de soins palliatifs. InfoKara. 1996;44:21-32.
59. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med. 1990;112:499-504.
60. Schwartz MK. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta. 1992;206:77-82.
61. Cassileth BR, Lusk EJ, Miller DS, Browne LL, Miller C. Psychosocial correlates of survival in advanced malignant disease? N Engl J Med. 1985;312:1551-1555.
62. Cassileth BR, Walsh W, Lusk EJ. Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol. 1988;6:1753-1759.
63. Coates A. Prognostic implications of quality of life. Cancer Treat Rev. 1993;19 (suppl A):53-57.
64. Morris JN, Suissa S, Sherwood S, Wright SM, Greer D. Last days: a study of the quality of life of terminally ill cancer patients. J Chronic Dis. 1986;39:47-62.
65. Morris JN, Sherwood S. Quality of life of cancer patients at different stages in the disease trajectory. J Chronic Dis. 1987;40:545-553.
66. Coates A, Gebsky V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment. N Engl J Med. 1987;317:1490-1495.
67. Coates A, Gebsky V, Signorini D, et al. Prognostic value of Quality of life score during chemotherapy for advanced breast cancer. J Clin Oncol. 1992;10:1833-1838.
68. Coates A, Thompson D, McLeod GRM, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without Interferon in patients with metastatic malignant melanoma. Eur J Cancer. 1993;29:1731-1734.
69. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171-175.
70. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage. 1996;11:32-41.
71. Ganz P, Lee J, Siau J. Quality of life assessment. Cancer. 1991;67:3131-3135.
72. Monnet E, Boutton MC, Faivre J, Milan C. Influence of socioeconomic status on prognosis of colorectal cancer: a population-based study in Cote d'Or, France, Cancer. 1993;72:1165-1170.
73. Cella D, Orav J, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9:1500-1509.
74. Goodwin JS, Samet JM, Hunt WC. Determinants of survival in older cancer patients. J Natl Cancer Inst. 1996;88:1031-1038.
75. Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med. 1994;9:314-320.
76. Jamison RN, Burish TG, Wallston KA. Psychogenic factors in predicting survival of breast cancer patients. J Clin Oncol. 1987;5:768-772.
77. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994;7:1350-1364.
78. Klastersky J, Daneau D, Verhest A. Causes of death in patients with cancer. Eur J Cancer. 1972;8:149-154.
79. Inagaki J, Rodriguez V, Bodey G. Causes of death in cancer patients. Cancer. 1973;2:568-573.
80. CANCERNET-PDQ [database online], Bethesda, Md: National Cancer Institute; 1996. Updated July 1996.
81. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS Multidimensional Functional Assessment Questionnaire. J Gerontol. 1981;36: 428-434.
82. Browne G, Jamieson E, Roberts J, Hay I. Modifications and Scoring of the OARS MFAQ Measure of Functional Capacity: 1991 Canadian Situation. Hamilton, Ontario: McMaster University: 1992. Working Paper Series, No. 92-8.
83. Bruera E, Carraro S, Roca E, Cedaro L, Chacon R. Association between malnutrition and caloric intake, emesis, psychological depression, glucose taste and tumor mass. Cancer Treat Rep. 1984;68:873-876.
84. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:199-205.
85. Zubrod CG, Sheiderman MA, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylenethiophosphoramide. J Chronic Dis. 1960;11:7-33.
86. Kaasa T, Loomis J, Gillis K, Bruera E, Hanson J. The Edmonton Functional Assessment Tool: preliminary development and evaluation for use in palliative care. J Pain Symptom Manage. 1997;13:10-19.
87. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients J Palliat Care. 1991;7:6-9.
88. Charlson ME, Ales KA, Pompei P, Mackenzie CR. A new method of classification of prognostic comorbidity for longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
89. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. J Psychiatr Res. 1975; 12:189-198.
90. Viganó A. Epidemiological, statistical and clinical aspects of research on prognostic factors in advanced/terminal cancer patients: reason for controversies. Paper presented at: Seventh Canadian National Palliative Care Conference; September 29, 1997; Saskatoon, Saskatchewan.
91. Viganó A, Bruera E, Suarez-Almazor ME. Survival predictors in advanced cancer patients. Paper presented at: Twelfth International Congress on the Care of the Terminally III; September 17, 1998; Montreal, Quebec.
92. Kaplan EL, Meier P. Non-parametric estimations for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
93. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
94. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. New York, NY: John Wiley & Sons Inc; 1995.
95. Stablein DM. Analysis of survival data with nonproportional hazard functions. Control Clin Trials. 1981;2:149-159.
96. Therneau T, Grambsh P, Fleming TR, Martingale-based residuals for survival models. Biometrika. 1990;77:147-160.
97. Belsey DA, Kuh E, Welsh RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York, NY: John Wiley & Sons Inc; 1980.
98. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499-503.
99. Statistics and Epidemiological Research Corporation. EGRET. Seattle, Wash: SERC; 1989.
100. SPSS Inc. SPSS for Windows: Base System User's Guide, Release 6.0. Chicago, III: SPSS Inc; 1993:350.
101. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981;34:2540-2550.
102. Arsenau JC, Carnellos GP, Banks PM. American Burkitt's lymphoma: clinicopathologic study of 30 cases. Am J Med. 1975;58:314-321.
103. Breton HD, Simon R, Pomeroy TC. Pretreatment lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Ann Intern Med. 1975;83:352-354.
104. Fatzinger P, DeMeester TR, Darakjian H, et al. The use of serum albumin for further classification of Stage III non-oat cell lung cancer and its therapeutic implications. Ann Thorac Surg 1984;37:115-122.
105. Bozzetti F, Migliavacca S, Scotti A, et al. Impact of cancer type and treatment on nutritional status of patients. Ann Surg. 1982;196:170-179.
106. Muers MF, Shelvin P, Brown J, for the participating members of the Thoracic Group of the Yorkshire Cancer Organization. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax. 1996; 51:894-902.
107. Perreira J. Bruera E. Chronic nausea. In: Bruera E, Higginson I, eds. Cachexia-Anorexia in Cancer Patients, New York, NY: Oxford University Press; 1996.
108. Bruera E, Chadwick S, MacDonald N, et al. Study of cardiovascular autonomic insufficiency in advanced cancer patients. Cancer Treat Rep. 1986;70:1383-1387.
109. Lavin PT, Bruckner HW, Plaxe SC. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer. 1982;50:2016-2023.
110. De Brauw LM, Van De Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol. 1987;34:81-86.
111. Schlichting P, Christensen E, Andersen PK, et al. Prognostic factors in cirrhosis identified by the Cox's regression model. Hepatology. 1983;3:889-895.